Differential antibiotic-induced endotoxin release in severe melioidosis

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1014-1019

  Simpson, A J H ^a,c   Opal, Steven M ^d,f   Angus, B J ^a,c   Prins, J M ^e   Palardy, J E ^d   Parejo, N A ^d   Chaowagul, W ^b   White, N J ^a,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sappasitthiprasong Hospital   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BROWN UNIVERSITY   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CHLORAMPHENICOL DERIVATIVE; COTRIMOXAZOLE; CYTOKINE; DOXYCYCLINE; ENDOTOXIN; IMIPENEM;

ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MELIOIDOSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THAILAND;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CYTOKINES; ENDOTOXINS; FEMALE; HUMANS; IMIPENEM; MALE; MELIOIDOSIS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0034037592     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315306     Document Type: Article

References (33)

1. 1. Leelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis 1989;11:413-25.
2. 2. Sanford JP. Pseudomonas species (including melioidosis and glanders). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2003-9.
3. 3. Chaowagul W, White NJ, Dance DAB, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989;159:890-8.
4. 4. Currie B, Howard D, Nguyen VT, Withnall K, Merianos A. The 1990-1991 outbreak of melioidosis in the Northern Territory of Australia: clinical aspects. Southeast Asian J Trop Med Public Health 1993;24:436-43.
5. 5. White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989;2:697-701.
6. 6. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus cotrimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992;36:158-62.
7. 7. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994;19:846-53.
8. 8. Chaowagul W. Melioidosis: a treatment challenge. Scand J Infect Dis Suppl 1996;101:14-6.
9. 9. Jackson JJ, Kropp H. Beta-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP)-2-speciftc imipenem and PBP-3-specific ceftazidime. J Infect Dis 1992;165:1033-41.
10. 10. Dofferhoff ASM, Potthoff H, Bon VJJ, et al. The release of endotoxin, TNF, and IL-6 during the antibiotic treatment of experimental gram-negative sepsis. J Endotoxin Res 1995;2:37-44.
11. 11. Smith MD, Wuthiekanun V, Walsh AL, White NJ. Susceptibility of Pseudomonas pseudomallei to some newer β-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994;33: 145-9.
12. 12. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Scand J Infect Dis Suppl 1996;101:9-13.
13. 13. Bucklin SE, Morrison DC. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis 1995;172:1519-27.
14. 14. Dofferhoff ASM, Nijland JH, deVries-Hospers HG, et al. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis 1991;23:745-54.
15. 15. Shenep JL, Flynn PN, Barrelt FF, et al. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988;157:565-8.
16. 16. Maury E, Barakett V, Blanchard H, et al. Circulating endotoxin during initial antibiotic treatment for severe gram-negative bacteremic infections. J Infect Dis 1998;178:270-3.
17. 17. Hopkin DA. Too rapid destruction of gram-negative organisms. Lancet 1977;2:603-4.
18. 18. Prins JM, van Agtmael MA, Kuijper EJ, van Deventer SJH, Speelman P. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 1995;172:886-91.
19. 19. Prins JM, van Deventer SJH, Kuiper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994;38:1211-8.
20. 20. Byl B, Clevenbergh P, Kentos A, et al. Clinical relevance of the antibiotic-induced endotoxin release during the treatment of gram-negative infection: a randomized prospective study. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California. Washington, DC: ASM Publishers, 1998:38.
21. 21. Simpson AJH, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999;29:381-7.
22. 22. Walsh AL, Wuthiekanun V. The laboratory diagnosis of melioidosis. Br J Biomed Sci 1996;53:249-53.
23. 23. Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991;27(Suppl D):1-50.
24. 24. Suputtamongkol Y, Kwiatkowski D, Dance DAB, Chaowagul W, White NJ. Tumor necrosis factor in septicemic melioidosis. J Infect Dis 1992;165: 561-4.
25. 25. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DAB, White NJ. A prospective comparison of co-amoxiciav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1995;89:546-9.
26. 26. Chaowagul W, Suputtamongkol Y, Dance DAB, Rajchanuvong A, Pattara-Arechachai J, White NJ. Relapse in melioidosis: incidence and risk factors. J Infect Dis 1993;168:1181-5.
27. 27. Suputtamongkol Y, Hall AJ, Dance DAB, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994;23:1082-90.
28. 28. Perry MB, MacLean LL, Scholiaardt T, Bryan LE, Ho M. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun 1995;63:3348-52.
29. 29. Leeson NC, Fujihara I, Morrison DL. Evidence for lipopolysaccharide (LPS) as the predominant pro-inflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 1994;62:4975-80.
30. 30. Galpine JF. Chloramphenicol in typhoid fever. BMJ 1949;2:1047-8.
31. 31. Gardlund B, Siölin J. Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease seventy. J Infect Dis 1995;172:296-301.
32. 32. Matsuura M, Kawahata R, Ezaki T, Nakano M. Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. FEMS Microbiol Lett 1996;137:79-83.
33. 33. Opal SM, Yu RL Jr. Antiendotoxin strategies for the prevention and treatment of septic shock: new approaches and future directions. Drugs 1998;55:497-508.